Navigation Links
Novartis/Schering-Plough's Drug Will Replace AstraZeneca's Symbicort as Decision Resources' Clinical Gold Standard by 2012 for the Treatment of Asthma
Date:2/24/2009

A Therapy's Effect on Reduction of Exacerbations is the Attribute That Most Influences Physicians' Prescribing Decisions, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Novartis/Schering-Plough's indacaterol/mometasone will replace AstraZeneca's Symbicort as Decision Resources' proprietary clinical gold standard by 2012 for the treatment of asthma due to its once-daily dosing competitive advantage. In fact, because none of the therapies projected to launch within the next ten years are expected to offer advantages in efficacy over currently marketed long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combinations, Decision Resources' gold standard will be determined by incremental advantages in delivery, such as less-frequent daily dosing and a faster onset of action.

"Physicians we interviewed report that once-daily dosing has the potential to increase patient compliance. Patient compliance is important because asthma is a chronic disease that requires consistent administration of anti-inflammatory drugs to reduce disease severity and limit costly emergency healthcare," said Martin Quinn, analyst at Decision Resources.

The new report entitled Asthma: Emerging LABA/ICS Combinations Will Have a Difficult Time Differentiating Themselves from Existing Agents in the Class also finds that a therapy's effect on reducing exacerbations is the attribute that most influences physicians' prescribing decisions in asthma. Based on U.S. and European surveyed physicians, current and emerging therapies have no advantage over sales-leading GlaxoSmithKline's Advair/Seretide/Adoair on this attribute.

About the Report

Asthma: Emerging LABA/ICS Combinations Will Have a Difficult Time Differentiating Themselves from Existing Agents in the Class is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Natalia Morales              Elizabeth Marshall
    Decision Resources           Decision Resources, Inc.
    781-296-2691                 781-296-2563
    nmorales@dresources.com      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. The next generation: nanomagnets could replace semiconductors
2. Carbon nanotubes to be replaced by MoSIx nanowires in high-tech devices says new study
3. Ranier Technology Secures GBP8m Funding for its Cadisc Replacement Spinal Discs
4. The future of computing -- carbon nanotubes and superconductors to replace the silicon chip
5. Genomics Likely to Replace Traditional Drug Therapies in Treating CHF
6. NexGen Biofuels Ltd. Announces Plans to Replace its CFO With Local CFO
7. Half of Surveyed Physicians Expect to Replace Between 6 Percent and 15 Percent of Their Sustiva Prescriptions with Isentress
8. CoreValve Successfully Treats the First Pacific Rim Patients with Its ReValving System for Percutaneous Aortic Valve Replacement : Australia/New Zealand Regulatory-Cleared Evaluation Registry is Expected to Lead to Market Clearance for These Countries
9. Facet Solutions Completes Facet Joint and Disc Replacement Study
10. Stenum Hospital Does its 600th American Disc Replacement Surgery
11. Cold atoms could replace hot gallium in focused ion beams
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/10/2017)... ... October 10, 2017 , ... For the second ... a US2020 STEM Mentoring Award. Representatives of the FirstHand program travelled to Washington, ... from US2020. , US2020’s mission is to change the trajectory of STEM education ...
(Date:10/10/2017)... ... 10, 2017 , ... The Pittcon Program Committee is pleased ... scientists who have made outstanding contributions to analytical chemistry and applied spectroscopy. Each ... leading conference and exposition for laboratory science, which will be held February 26-March ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography ... generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase ...
Breaking Biology Technology:
(Date:4/4/2017)... , April 4, 2017   EyeLock LLC , ... that the United States Patent and Trademark Office (USPTO) ... covers the linking of an iris image with a ... and represents the company,s 45 th issued patent. ... is very timely given the multi-modal biometric capabilities that ...
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
Breaking Biology News(10 mins):